Plus Therapeutics, Inc.
$7.3
▼
-8.6%
2026-04-21 08:59:00
plustherapeutics.com
NCM: PSTV
Explore Plus Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$50.09 M
Current Price
$7.3
52W High / Low
$30.5 / $2.9
Stock P/E
—
Book Value
$0.72
Dividend Yield
—
ROCE
-381.4%
ROE
903.94%
Face Value
—
EPS
$-7.25
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
28
Beta
1.02
Debt / Equity
20.55
Current Ratio
1.23
Quick Ratio
1.23
Forward P/E
-2.04
Price / Sales
6.32
Enterprise Value
$25.15 M
EV / EBITDA
-1.69
EV / Revenue
4.82
Rating
Buy
Target Price
$38
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Amicus Therapeutics, Inc. | $14.46 | — | $4.54 B | — | 4.84% | -11.58% | $14.48 / $5.51 | $0.88 |
| 2. | Aclaris Therapeutics, Inc. | $4.25 | — | $512.53 M | — | -53.3% | -50.2% | $4.89 / $1.08 | $0.85 |
| 3. | MapLight Therapeutics, Inc. | $28.34 | — | $1.28 B | — | -36.5% | -56.19% | $31.13 / $12.24 | $10.41 |
| 4. | XOMA Royalty Corporation | $40 | 14.61 | $463.38 M | 1.18% | 4.79% | 34.12% | $40.74 / $20.59 | $7.07 |
| 5. | BioCardia, Inc. | $1.25 | — | $12.91 M | — | -843.83% | -9.5% | $3.2 / $1 | $0.08 |
| 6. | Artelo Biosciences, Inc. | $4.53 | — | $3.96 M | — | 917.46% | -16.25% | $85.8 / $2.96 | $-1.89 |
| 7. | Niagen Bioscience, Inc. | $4.87 | 22.44 | $389.99 M | — | 16.53% | 28.35% | $14.69 / $4.16 | $0.96 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -5.74 M | -4.48 M | -1.54 M | -3.54 M | -3.9 M | — |
| Net Profit | -5.71 M | -4.42 M | 5.15 M | -17.4 M | -3.9 M | — |
| EPS in Rs | -0.83 | -0.64 | 0.75 | -2.54 | -0.57 | -9.25 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -15.3 M | -14.7 M | -13.32 M | -19.71 M |
| Net Profit | -22.39 M | -12.98 M | -13.32 M | -20.27 M |
| EPS in Rs | -3.26 | -1.89 | -1.94 | -2.95 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 16.32 M | 6.63 M | 11.39 M | 23.87 M |
| Total Liabilities | 12.33 M | 15.58 M | 12.74 M | 17.42 M |
| Equity | 4 M | -8.95 M | -1.35 M | 6.45 M |
| Current Assets | 15.17 M | 5.26 M | 9.83 M | 21.82 M |
| Current Liabilities | 12.31 M | 15.55 M | 10.73 M | 11.85 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -20.77 M | -10.55 M | -12.85 M | -12.97 M |
| Investing CF | -0.85 M | -4.11 M | -0.16 M | -0.76 M |
| Financing CF | 30.31 M | 6.19 M | 3.44 M | 13.45 M |
| Free CF | -20.84 M | -11.24 M | -13.01 M | -13.73 M |
| Capex | -0.07 M | -0.69 M | -0.16 M | -0.76 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 2.54% | 34.32% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-04-02 | 1:0.04 |
| 2023-05-01 | 1:0.0666667 |